$SRZN SEC Filings

Filed On	Filing
22 Oct 2026	Form 4: Column Group Iii GP, Lp, 10% owner and 6 others Received 1,551,724 shares by exercise ($18M) · Acquired 775,862 Series E Common Warrants (In/At-money Exercise)
22 Oct 2026	Form 4: Kutzkey Tim, Director Received 1,551,724 shares by exercise ($18M) · Acquired 775,862 Series E Common Warrants (In/At-money Exercise)
22 Oct 2026	SCHEDULE 13D/A
20 Oct 2026	8-K: Results of Operations and Financial Condition; Unregistered Sales of Equity Securities Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143
07 Oct 2026	SCHEDULE 13G/A
02 Oct 2026	8-K: Other Events On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The I...
01 Oct 2026	SCHEDULE 13G
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
11 Aug 2026	SCHEDULE 13G/A
07 Aug 2026	25-NSE
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
24 Jul 2026	SCHEDULE 13G/A
24 Jul 2026	Form 4: Tcg Crossover Gp II, Llc, 10% owner and 4 others Sold 325,000 shares ($6.91M)
16 Jun 2026	Form 4: Maleki Andrew Pedrum, Chief Financial Officer Received 607 shares as a grant or award ($11.5K)
16 Jun 2026	Form 4: Li Yang, Exec. Vice President, Research Received 1,666 shares as a grant or award ($13.5K)
16 Jun 2026	Form 4: Williams Charles O, Chief Operating Officer Received 1,666 shares as a grant or award ($13.5K)
16 Jun 2026	Form 4: Parker Craig C, Director Received 1,622 shares as a grant or award ($13.2K)

Comments